Study title |
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment (AHFIRM) |
Disease or condition |
Alcoholic Hepatitis |
Study type |
Intervention (Clinical Trial) |
Intervention/treatment |
DUR-928 30 mg, DUR-928 90 mg, or Placebo+Standard of Care (SOC) |
Phase |
2b |
Study site |
Carolinas Medical Center, Center for Liver Disease & Transplant (Atrium Health) |
Study location |
Charlotte, NC |
Principal investigator name and email |
Mark Russo, MD |
Study coordinator name and email |
Marybeth Schwallie@atriumhealth.org |
Phone contact |
704-355-7608 |
Clinicaltrials.gov link |
https://clinicaltrials.gov/ct2/show/NCT04563026 |